Results 11 to 20 of about 44,548 (260)
The Microenvironment in Myeloproliferative Neoplasms [PDF]
Hematology/Oncology Clinics of North America, 2021 Chronic inflammation is a hallmark of myeloproliferative neoplasms (MPNs), with elevated levels of proinflammatory cytokines being commonly found in all 3 subtypes. Systemic inflammation is responsible for the constitutional symptoms, thrombosis risk, premature atherosclerosis, and disease evolution in MPN.
Ramanathan, Gajalakshmi +1 more
openaire +3 more sources
Myeloproliferative neoplasms [PDF]
Clinical Medicine, 2013 The myeloproliferative neoplasms that are associated with the JAK2 mutation are a heterogeneous group of disorders. The additional mutations that result in the clinical phenotype are still the subject of research. As more than one mutation is involved, and as JAK2 has a necessary physiological role (unlike BCR-ABL), the development of targeted therapy ...
Amy, Publicover, Patrick, Medd
openaire +3 more sources
Epigenetics in myeloproliferative neoplasms
Frontiers in Oncology, 2023 The myeloproliferative neoplasms (MPNs) are a group of acquired clonal disorders where mutations drive proliferative disease resulting in increased blood counts and in some cases end-stage myelofibrosis. Epigenetic changes are the reversible modifications to DNA- and RNA-associated proteins that impact gene activity without changing the DNA sequence ...
Greenfield, Graeme +1 more
openaire +4 more sources
Genomics of Myeloproliferative Neoplasms [PDF]
Journal of Clinical Oncology, 2017 Myeloproliferative neoplasms (MPNs) are a group of related clonal hematologic disorders characterized by excess accumulation of one or more myeloid cell lineages and a tendency to transform to acute myeloid leukemia. Deregulated JAK2 signaling has emerged as the central phenotypic driver of BCR -ABL1–negative MPNs and a unifying therapeutic target. In
Zoi, Katerina, Cross, Nicholas
openaire +2 more sources
Morphology of myeloproliferative neoplasms
International Journal of Laboratory Hematology, 2023 AbstractMyeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia‐negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre‐fibrotic myelofibrosis and primary myelofibrosis (PMF).
Zi Yun Ng +3 more
openaire +2 more sources
Update in the myeloproliferative neoplasms [PDF]
Clinical Medicine, 2014 The differential diagnosis of haematological abnormalities, such as leucocytosis, erythocytosis, thrombocytosis or indeed anaemia, is wide and disarming. Here we report on significant updates in the differential diagnosis of erythrocyosis and thrombocytosis presenting a simplified schema for the clinician.
Harrison, Claire N, McMullin, Mary F
openaire +3 more sources
Myeloproliferative Neoplasms [PDF]
JAMA Oncology, 2015 Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are ...
Ayalew, Tefferi, Animesh, Pardanani
openaire +2 more sources
Haematologica, 2014 According to the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues, myeloproliferative neoplasms (MPN) include chronic myeloid leukemia and the so-called Philadelphia-negative myeloproliferative neoplasms, i.e.
Luca Malcovati +2 more
doaj +4 more sources
Aetiology of Myeloproliferative Neoplasms [PDF]
Cancers, 2020 Myeloproliferative neoplasms (MPNs) have estimated annual incidence rates for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis of 0.84, 1.03, and 0.47 per 100,000. Prevalence is much higher, particularly for PV and ET, as mortality rates are relatively low.
Mary Frances McMullin +1 more
openaire +4 more sources